A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
Approval of a cystic fibrosis triplet from Vertex looks odds-on – and with the competition lagging behind, the company has free rein on price.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Split congressional control will result in more drug pricing talk, but don’t expect much action.
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.